Does Dextromethorphan Show Up in a Drug Test?

Dextromethorphan (DXM), the cough suppressant found in dozens of over-the-counter cold medicines, does not typically trigger a positive result on a standard drug test at recommended doses. However, it can cause false positives on certain screening panels, particularly for phencyclidine (PCP) and, in rarer cases, for opiates. The risk climbs with higher doses and varies depending on which test kit a lab or employer uses, which makes this a more complicated question than a simple yes or no.

The PCP False-Positive Problem

The most well-documented issue with DXM and drug tests involves PCP screening. Standard urine drug screens use a class of tests called immunoassays, which work by detecting chemical shapes that resemble the target drug. DXM’s molecular structure is similar enough to PCP’s that it can bind to the antibodies in certain PCP screening assays and register as a positive result even when the person has never been anywhere near PCP.

A study examining medication records alongside PCP urine screen results found that dextromethorphan was one of several common medications significantly associated with false-positive PCP screens.¹ Other medications on that list included tramadol, alprazolam, clonazepam, and the heart medication carvedilol, but DXM stands out because of how widely it is used. Millions of people take DXM-containing cold medications each year without ever thinking about drug-test implications.

This cross-reactivity issue is not a quirk of one specific test brand. The phenomenon has been documented across multiple screening platforms, which means it can happen whether you are tested at a workplace clinic, a hospital emergency department, or a probation office.² The practical upshot is that if you have recently taken a cold medicine containing DXM and you are screened for PCP, there is a real chance of a false positive appearing on your initial results.

Can DXM Trigger a Positive Opiate Screen?

This is where the picture gets more nuanced. DXM is technically an opioid derivative. It is synthesized from levorphanol, which belongs to the opioid family, and this ancestry is one reason people assume it will flag an opiate panel. In practice, though, the evidence is mixed and depends heavily on dose.

One controlled study gave young adults DXM at two different dosage levels and then ran urine EMIT assays (a common immunoassay platform) six hours later. Every single opioid screen came back negative, across both doses. By contrast, the same study confirmed that codeine, a true opiate, produced positive screens as expected.³ At normal therapeutic doses, DXM simply does not register on most opiate immunoassays.

The story changes at high doses. A more recent case report documented a patient who had ingested a large amount of dextromethorphan and produced what appeared to be a false-positive opiates screen on rapid urine drug testing. Follow-up investigation using multiple screening assays and spiked drug-free urine samples showed that some opiate screening assays are susceptible to DXM cross-reactivity when concentrations are high enough.⁴ “High enough” typically means recreational misuse levels, not the amount you would get from following the label on a bottle of cough syrup.

So the short version: at normal doses, DXM is unlikely to trigger an opiate false positive. At abuse-level doses, certain test platforms can be fooled. The PCP false-positive risk, by comparison, seems to be more sensitive and can show up at lower concentrations.

Why Dose and Metabolism Both Matter

The amount of DXM you take is the most obvious variable, but it is not the only one that determines how much of the drug and its breakdown products end up in your urine. Your body processes DXM primarily through a liver enzyme called CYP2D6, which converts it into a metabolite called dextrorphan.⁵ How fast or slow that conversion happens depends on your genetics.

CYP2D6 is one of the most genetically variable drug-metabolizing enzymes in humans. Roughly 5 to 10 percent of people of European descent are “poor metabolizers,” meaning their version of the enzyme works slowly or barely at all. These individuals break down DXM much more slowly, which means the parent drug hangs around at higher concentrations in the blood and urine for longer. On the other end, some people are “ultra-rapid metabolizers” who clear DXM very quickly. Modeling studies have confirmed that these genetic differences produce wide variation in DXM and dextrorphan levels across individuals, even when everyone takes the same dose.⁶

This matters for drug testing because the cross-reactivity risk depends partly on how much DXM and dextrorphan are present in the urine sample. A poor metabolizer who takes a standard dose might end up with urine DXM concentrations closer to those of a normal metabolizer who took a much larger dose. The practical consequence is that two people taking the same cough syrup from the same bottle could have meaningfully different risks of triggering a false positive.

Other medications can also affect this equation. Drugs that inhibit CYP2D6, including common antidepressants like fluoxetine (Prozac) and paroxetine (Paxil), slow DXM metabolism and raise its levels. If you are taking one of these medications and also using a DXM-containing cough product, the effective concentration in your body could be higher than the label dose would suggest. This is worth keeping in mind if you know you have an upcoming drug screen.

What Happens After a Positive Screen

A positive result on an initial immunoassay screening test is not the end of the story. In most workplace, legal, and clinical settings, a positive screen is followed by a confirmatory test using a different, more precise technology. The gold standard for confirmation has long been gas chromatography-mass spectrometry (GC-MS), though liquid chromatography-tandem mass spectrometry (LC-MS/MS) is also widely used. These methods identify the exact molecules present in a sample rather than relying on shape-matching antibodies, which means they can distinguish DXM from PCP or morphine without difficulty.

The study that identified DXM as a cause of false-positive PCP screens used GC-MS confirmation as a routine step. Results were classified as either confirmed (a true positive for PCP) or failed to confirm (a false positive), and the false positives linked to DXM fell into the latter category.¹ In other words, confirmatory testing reliably catches DXM-related false positives. If you are tested in a setting that uses a two-step process, a false positive from cough medicine should be cleared at the confirmation stage.

The problem arises in settings where confirmatory testing is not routinely performed. Some point-of-care test cups used in urgent care clinics, rehabilitation facilities, or probation offices report results based on the immunoassay alone. At-home drug tests you can buy at a pharmacy also give you only the initial screen result. In these situations, a false positive from DXM can look exactly the same as a true positive for PCP, and there is no automatic second step to correct it. If you find yourself in this scenario, you should request confirmatory testing and mention your DXM use to whoever is administering the test.

When Labs Test Specifically for DXM

Standard workplace and forensic drug panels do not look for dextromethorphan itself. The typical 5-panel or 10-panel urine tests screen for categories of drugs like amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP. DXM is not one of the targets, which means in most testing scenarios the question is only about cross-reactivity and false positives, not about the lab intentionally looking for DXM.

There are exceptions. Some pain management clinics and substance-abuse treatment programs order expanded panels that specifically include DXM as a target analyte. This is partly because DXM abuse has become a recognized concern, especially among adolescents and young adults, and partly because DXM can interfere with other pain medications in ways clinicians need to monitor. Specialized LC-MS/MS methods have been developed that can detect and quantify both DXM and its metabolite dextrorphan in oral fluid at concentrations as low as 5 nanograms per milliliter.⁷ When these specialized tests are in play, even therapeutic use of cough medicine will show up, and the result will not be a false positive for another drug but rather a genuine positive for DXM.

If you are in a pain management program or a treatment setting that monitors for DXM, taking any cough product containing it will likely show up. Mention it to your provider ahead of time so there is a record of legitimate use. This kind of transparency matters because a lab reporting a positive DXM result cannot distinguish between someone who took Robitussin for a cold and someone who misused DXM recreationally. Context from the patient fills that gap.

Prescription DXM Products and Testing

DXM is not only found in over-the-counter cough medicines. It is also an active ingredient in a prescription medication called Nuedexta (dextromethorphan combined with quinidine), which is approved for pseudobulbar affect, a neurological condition that causes uncontrollable episodes of laughing or crying. A newer DXM-containing prescription, Auvelity (dextromethorphan plus bupropion), is approved for major depressive disorder.

The quinidine in Nuedexta is specifically included to inhibit CYP2D6 and keep DXM levels higher in the bloodstream for therapeutic effect.⁵ This means patients on Nuedexta may have sustained elevated DXM concentrations compared to someone who takes a one-off dose of cough syrup. The cross-reactivity risk on PCP and opiate screens could, in theory, be somewhat higher for these patients, though formal studies quantifying that specific risk in Nuedexta users are sparse. If you are prescribed one of these medications, documenting it with whoever administers your drug testing is especially important.

Practical Steps If You Are Facing a Drug Test

If you have a scheduled drug test and you have recently taken a DXM-containing cough or cold product, here is what to keep in mind:

Disclose upfront: Tell the testing administrator or medical review officer (MRO) that you have been taking an over-the-counter cough medicine containing dextromethorphan. In workplace testing under federal guidelines, the MRO reviews positive results before they are reported to the employer and is trained to evaluate legitimate medication use.
Request confirmation: If your initial screen comes back positive for PCP or opiates and you believe DXM is the cause, request confirmatory testing by GC-MS or LC-MS/MS. This step should rule out the false positive.
Keep the packaging: Hold onto the box or bottle of whatever cold medicine you took. Having the product label available makes it easier to demonstrate that your DXM exposure was from a legal, over-the-counter source.
Know the timing: DXM and its metabolites are generally cleared from urine within one to two days after a single therapeutic dose, though this varies with individual metabolism. If your test is several days away, the risk drops considerably.

One thing that will not help is trying to claim DXM as an explanation for a confirmed positive for an illicit drug. The controlled study that examined the “dextromethorphan defense” found that DXM at therapeutic doses did not produce positive opioid screens, and confirmatory testing distinguishes DXM from true opiates and PCP with high accuracy.³ Labs and MROs are aware that some people invoke cough medicine as a cover story, and confirmatory chemistry makes that story verifiable one way or the other.